Sino Biopharmaceutical was among the participants in a round valuing the drug development technology provider at over $2bn.

XtalPi, the China-based creator of an artificial intelligence-equipped drug discovery system, has raised $400m in series D funding from investors including pharmaceutical company Sino Biopharmaceutical, DealStreetAsia reported today.

Healthcare investment firm OrbiMed’s Healthcare Fund Management co-led the round with alternative asset management firm Hopu Investments, and it also featured venture capital firms Sequoia Capital China and 5Y Capital. It valued the company above $2bn.

Founded in 2014, XtalPi has created a digital drug discovery platform that utilises artificial intelligence to…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn